Multiple epidermal growth factor-like domains protein 10 (MEGF10) is an emerging transmembrane receptor essential for phagocytosis, apoptotic cell clearance (efferocytosis), and myogenesis. Primarily expressed in the central nervous system (astrocytes and microglia) and skeletal muscle satellite cells, MEGF10 is a critical target under investigation for neurodegenerative diseases—such as Alzheimer's disease, where it mediates Amyloid-beta clearance—and rare muscular dystrophies like MEGF10-related myopathy (EMARDD). Developing therapeutics targeting MEGF10 requires highly native, conformationally intact proteins and robust cell-based expression systems to accurately evaluate ligand binding and phagocytic activation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MEGF10 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MEGF10 ECD-Fc Recombinant Protein HEK293 expressed for native glycosylation. High purity (>95% by SDS-PAGE), Endotoxin controlled (<1.0 EU/μg). Sequence Verified. Suitable for binding assays and SPR. |
View MEGF10 Products |
| Gene Delivery | MEGF10 Promise-ORF / Lentivirus Full-length human MEGF10 ORF in lentiviral vector. Ideal for establishing stable phagocytic cell lines (e.g., in microglia or astrocytes) without transfection-induced toxicity. |
View MEGF10 Products |
| Benchmark Ab | Anti-MEGF10 Benchmark Antibody Recombinant monoclonal antibody sequence-matched to clinical/validation clones. Serves as a positive control for flow cytometry and functional blocking assays. |
View MEGF10 Products |
| Validator | MEGF10 siRNA Set Target-specific siRNA pool for target validation and knockdown-mediated specificity controls in efferocytosis assays. |
View MEGF10 Products |
| Related Target A | MERTK Co-receptor/parallel pathway in phagocytosis and efferocytosis; crucial for counter-screening and synergy studies in neuroinflammation. |
View MERTK Products |
| Related Target B | Amyloid-beta (Abeta) Primary pathological substrate cleared by MEGF10-mediated astrocytic phagocytosis in Alzheimer's disease models. |
View ABETA Products |
| Related Target C | C1q Complement component that acts as an opsonin, binding to apoptotic cells and bridging them to MEGF10 to initiate engulfment. |
View C1Q Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining Native Disulfide-rich Conformation | HEK293 eukaryotic expression system ensures correct folding of the multiple EGF-like domains and post-translational glycosylation. |
| Low-Affinity Ligand Interaction Detection | High-purity ECD-Fc fusion proteins maximize avidity, enabling sensitive SPR, BLI, and ELISA screening. |
| Stable Overexpression in Primary Glial Cells | High-titer, integration-competent Lentiviral particles optimized for hard-to-transfect microglia and astrocytes. |
| Assay Specificity and Off-Target Control | Sequence-verified siRNA knockdown reagents provide absolute negative controls to validate MEGF10-specific pharmacology. |
Live MEGF10 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of MEGF10 is expanding beyond its classical association with rare congenital myopathies into the high-stakes arena of neurodegeneration and neuroimmunology. As astrocytes and microglia are increasingly recognized as primary drivers of synaptic pruning and proteinopathy clearance, MEGF10 has emerged as a key receptor mediating the uptake of neurotoxic aggregates, including Amyloid-beta and tau. Current drug discovery efforts are shifting from basic target validation toward the development of agonist monoclonal antibodies or small molecule modulators designed to upregulate MEGF10-mediated phagocytosis in the aging brain. Concurrently, gene therapy approaches utilizing adeno-associated virus (AAV) or lentiviral vectors are being explored to restore MEGF10 expression in patients suffering from Early-Onset Myopathy, Areflexia, Respiratory Distress, and Demyelinating Polyneuropathy (EMARDD).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonist Antibodies | Academic Medical Centers, Biotech Startups | Alzheimer's Disease, Parkinson's Disease | Functional activation assays requiring high-purity, native MEGF10-ECD proteins to screen for epitope-specific binding. |
| Gene Therapy (Lentivirus/AAV) | Orphan Drug Developers | EMARDD (MEGF10 Myopathy) | Target validation tools, including MEGF10 siRNA and Western Blot positive controls, to verify transgene expression and rescue. |
| Small Molecule Modulators | Neuro-immunology Focused Biopharma | Neuroinflammatory Disorders, Synaptic Pruning | High-throughput cell-based screening lines generated using MEGF10 Lentiviral transduction. |